Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

Biocon Biologics on Thursday said it has received an approval from the US health regulator to market a cancer treatment ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

The US sales of bevacizumab were around $2 billion in 2023. Amgen, Amneal, Celltrion and Pfizer are its competitors in the US ...

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...

Download this technical note to explore how a qualitative, real-time, high-throughput in vitro tube formation assay helps ...

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

The tripeptide glycyl-L-histidyl-L-lysine (GHK), when complexed with copper ions to form GHK-Cu, has garnered attention for ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...